Compare RDNT & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDNT | BLLN |
|---|---|---|
| Founded | 1985 | 2016 |
| Country | United States | United States |
| Employees | N/A | 713 |
| Industry | Medical Specialities | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 5.2B |
| IPO Year | 1996 | N/A |
| Metric | RDNT | BLLN |
|---|---|---|
| Price | $60.67 | $118.17 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 7 |
| Target Price | $82.80 | ★ $126.71 |
| AVG Volume (30 Days) | ★ 844.5K | 782.3K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,616,630,000.00 | N/A |
| Revenue This Year | $22.78 | $46.29 |
| Revenue Next Year | $10.70 | $30.14 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 13.05 | N/A |
| 52 Week Low | $50.79 | $61.96 |
| 52 Week High | $85.84 | $138.70 |
| Indicator | RDNT | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 60.81 | 67.16 |
| Support Level | $58.46 | $79.07 |
| Resistance Level | $59.98 | $138.70 |
| Average True Range (ATR) | 2.86 | 6.87 |
| MACD | 0.55 | 1.10 |
| Stochastic Oscillator | 85.30 | 97.91 |
RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments: Imaging Center segment and Digital Health segment. The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), and fluoroscopy. The Digital Health segment develops and deploys clinical applications to enhance the interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostic.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.